PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions

The use of immune checkpoint inhibitors (ICIs) has become one of the most promising approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells, such as chemotherapy, radiotherapy, or targeted therapy, ICIs directly restore the exhausted host antitumor immune resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Liliang, Liu, Yuanyong, Wang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394772/
https://www.ncbi.nlm.nih.gov/pubmed/30819829
http://dx.doi.org/10.1634/theoncologist.2019-IO-S1-s05

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394772/
https://www.ncbi.nlm.nih.gov/pubmed/30819829
http://dx.doi.org/10.1634/theoncologist.2019-IO-S1-s05

Ejemplares similares